Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of Long-Acting Injectable Paliperidone Palmitate on Clinical and Functional Outcomes in Patients With Schizophrenia Based on Illness Duration
Seoyoung Kim, SuYoun Kim, MinJung Koh, et al.
The Journal of Clinical Psychiatry (2021) Vol. 82, Iss. 1
Open Access | Times Cited: 21

Showing 21 citing articles:

Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
John M. Kane, Joseph P. McEvoy, Christoph U. Correll, et al.
CNS Drugs (2021) Vol. 35, Iss. 11, pp. 1189-1205
Open Access | Times Cited: 50
Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges
Peter Haddad, Christoph U. Correll
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 4, pp. 473-493
Closed Access | Times Cited: 20
Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: treatment goals and approaches to functional recovery
Celso Arango, Andrea Fagiolini, Philip Gorwood, et al.
BMC Psychiatry (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 12
An analysis of the clinical application of paliperidone palmitate injection based on real-world
Ruixue Liu, Chunxiao Liu, Di Hu, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Assessment of functional recovery in patients with schizophrenia, with a focus on early-phase disease: results from a Delphi consensus and narrative review
Philip Gorwood, Murat Yıldırım, Jessica Madera-McDonough, et al.
BMC Psychiatry (2025) Vol. 25, Iss. 1
Open Access
Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosis
Marco Solmi, Heidi Taipale, Minna Torniainen‐Holm, et al.
American Journal of Psychiatry (2022) Vol. 179, Iss. 12, pp. 938-946
Closed Access | Times Cited: 14
Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM
Robert E. Litman, Dieter Naber, Lourdes Anta, et al.
Neuropsychiatric Disease and Treatment (2023) Vol. Volume 19, pp. 219-232
Open Access | Times Cited: 8
Characteristics of patients with schizophrenia switching from oral antipsychotics to once-monthly paliperidone palmitate (PP1M): a systematic review
Qian Li, Xin Li, Chong Ye, et al.
BMC Psychiatry (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Comparative effectiveness and safety of antipsychotic drugs in patients with schizophrenia initiating or reinitiating treatment: A Real‐World Observational Study
Sébastien Brodeur, Alain Vanasse, Josiane Courteau, et al.
Acta Psychiatrica Scandinavica (2022) Vol. 145, Iss. 5, pp. 456-468
Closed Access | Times Cited: 9
Impact on functionality of the paliperidone palmitate three-month formulation in patients with a recent diagnosis of schizophrenia: a real-world observational prospective study
María Paz García‐Portilla, Adolfo Benito Ruiz, Felisa Gómez Robina, et al.
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 5, pp. 629-638
Open Access | Times Cited: 7
Switching from risperidone to paliperidone palmitate in schizophrenia: Changes in social functioning and cognitive performance
Meritxell Tost, Alex González-Rodríguez, Raquel Aguayo, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2022) Vol. 120, pp. 110619-110619
Closed Access | Times Cited: 5
Effects of Long-acting Injectable 3-Monthly Paliperidone Palmitate on the Clinical and Social Performance of Patients with Schizophrenia
Jihoon Oh, Jihye Oh, Dong Wook Kim, et al.
Clinical Psychopharmacology and Neuroscience (2023) Vol. 21, Iss. 1, pp. 126-134
Open Access | Times Cited: 2
Medications for Psychosis: Dopamine Blockers and Dopamine Partial Agonists (Antipsychotics)
Hiroyuki Uchida, Euitae Kim, L. Fredrik Jarskog, et al.
Springer eBooks (2023), pp. 1-58
Closed Access | Times Cited: 2
Comparison of health resource usage and costs associated with first-generation and second-generation long-acting injectable antipsychotics for patients with schizophrenia: A nationwide population-based cohort study
Chuan-Pin Yang, Pei-Ning Wu, L. R. Liao, et al.
Asian Journal of Psychiatry (2023) Vol. 89, pp. 103789-103789
Closed Access | Times Cited: 2
Patients’ awareness of recovery mediates the link between clinical and level of functional remission in schizophrenia to a larger extent in those treated with long-acting antipsychotics
Jasmina Mallet, Clément Dondé, Caroline Dubertret, et al.
Therapeutic Advances in Psychopharmacology (2024) Vol. 14
Open Access
Transitions for Young Adults with Psychosis and Mania
Arya Shah, Matthew L. Baum, Andrew R. Pines, et al.
Springer eBooks (2024), pp. 193-202
Closed Access
Medications for Psychosis: Dopamine Blockers and Dopamine Partial Agonists (Antipsychotics)
Hiroyuki Uchida, Euitae Kim, L. Fredrik Jarskog, et al.
Springer eBooks (2024), pp. 4123-4180
Closed Access
Introducing S.C.O.P.E.™ (Schizophrenia Clinical Outcome Scenarios and Patient–Provider Engagement), an Interactive Digital Platform to Educate Healthcare Professionals on Schizophrenia Care
Christoph U. Correll, José M. Rubio, Leslie Citrome, et al.
Neuropsychiatric Disease and Treatment (2024) Vol. Volume 20, pp. 1995-2010
Open Access
Dynamics of clinical manifestations and social functioning in schizophrenia: a non-interventional observational study of paliperidone palmitat dosage forms
A M Reznik, Olga Karpenko, Е. А. Шумакова, et al.
Consortium Psychiatricum (2024) Vol. 5, Iss. 4, pp. 16-38
Open Access
Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: Treatment goals and approaches to functional recovery
Celso Arango, Andrea Fagiolini, Philip Gorwood, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 1
Cost-utility analysis of using paliperidone palmitate in schizophrenia in China
Rui Luo, Lu H, Hengfen Li
Frontiers in Pharmacology (2023) Vol. 14
Open Access
Page 1

Scroll to top